ANGELA MOSER: Open Payments
NPI 1750641882 · LINCOLN, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,625 in 66 payments from 15 companies in 2025. Trend: 2023 $1,148 · 2024 $1,544 · 2025 $1,625
Food & beverage: $1,625
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 30 | $787 |
| AstraZeneca Pharmaceuticals LP | 10 | $279 |
| Novartis Pharmaceuticals Corporation | 5 | $84 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $75 |
| CSL Behring | 3 | $75 |
| PFIZER INC. | 2 | $59 |
| Grifols USA, LLC | 2 | $48 |
| Regeneron Healthcare Solutions, Inc. | 2 | $38 |
| BioCryst US Sales Co., LLC | 2 | $36 |
| Lilly USA, LLC | 2 | $35 |
Products named: DUPIXENT, FASENRA, AIRSUPRA, AYVAKIT, Hizentra, XOLAIR, CUVITRU, Prolastin-C Liquid.
Industry payments across NE — which companies pay providers there.
